Skip to content

Study · Systematic review · 2025

13 results

Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.

Xiao YJ, Yu S, Zhang YL, Chen J, Liu YQ, Liu XL, Sun CF, Deng CL

Diabetes, obesity & metabolism8 Sept 2025Cited by 1 (Europe PMC)

PMID40922121 (opens in a new tab)DOI10.1111/dom.70105 (opens in a new tab)PepBankPUB-40922121
Publisher pagePubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a meta-analysis of adults in six RCTs, survodutide significantly reduced HbA1c versus placebo (WMD -0.66%).

    In plain wordsIn a pooled analysis of adult trials, survodutide lowered HbA1c more than placebo.

    Peptide
    Survodutide
    Outcome
    DecreaseHbA1c change
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    HbA1c weighted mean difference
    −0.66%
    survodutide vs placebo
    95% CI
    −1.08 to −0.23%
    survodutide vs placebo

    Source sentences

    Summary
    Compared with placebo, survodutide significantly reduced HbA1c (weighted mean difference [WMD]: -0.66%, 95% confidence interval [CI] [-1.08, -0.23], p = 0.002)
    2 context sentences
    Summary · context
    We systematically searched PubMed, Embase, the Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov for randomized controlled trials (RCTs) evaluating the efficacy and safety of survodutide up to 12 July 2025.
    Summary · context
    Six RCTs involving 1272 participants were included in this meta-analysis.
  2. 02HumanSystematic reviewEfficacy outcome

    In a meta-analysis of adults in six RCTs, survodutide significantly reduced fasting glucagon levels versus placebo (WMD -7 pmol/L).

    In plain wordsIn a pooled analysis of adult trials, survodutide lowered fasting glucagon levels more than placebo.

    Peptide
    Survodutide
    Outcome
    DecreaseFasting glucagon change
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Fasting glucagon weighted mean difference
    −7 pmol/L
    survodutide vs placebo

    Source sentences

    Summary
    fasting glucagon levels (WMD: -7 pmol/L, 95% CI [-10.3, -3.69], p = 0.016)
    2 context sentences
    Summary · context
    We systematically searched PubMed, Embase, the Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov for randomized controlled trials (RCTs) evaluating the efficacy and safety of survodutide up to 12 July 2025.
    Summary · context
    Six RCTs involving 1272 participants were included in this meta-analysis.
  3. 03HumanSystematic reviewEfficacy outcome

    In a meta-analysis of adults in six RCTs, the HbA1c reduction was greater with a total weekly survodutide dose above 2.4 mg than with a total weekly dose of 2.4 mg or less.

    In plain wordsIn a pooled analysis of adult trials, higher weekly survodutide doses above 2.4 mg lowered HbA1c more than lower doses.

    Peptide
    Survodutide
    Outcome
    DecreaseHbA1c change by total weekly dose
    Study

    n: not reported in source

    Comparator
    Survodutide total weekly dose of 2.4 mg or less
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Total weekly dose threshold
    > 2.4 mg
    higher-dose subgroup

    Source sentences

    Summary
    Greater reductions were observed in the subgroup receiving a total weekly dose of >2.4 mg compared with the subgroup receiving ≤2.4 mg weekly.
    3 context sentences
    Summary · context
    A greater reduction in HbA1c was specifically associated with a higher total weekly dose (>2.4 mg)
    Summary · context
    We systematically searched PubMed, Embase, the Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov for randomized controlled trials (RCTs) evaluating the efficacy and safety of survodutide up to 12 July 2025.
    Summary · context
    Six RCTs involving 1272 participants were included in this meta-analysis.
  4. 04HumanSystematic reviewEfficacy outcome

    In a meta-analysis of adults in six RCTs, survodutide significantly decreased body weight versus placebo (WMD -6.7 kg).

    In plain wordsIn a pooled analysis of adult trials, survodutide lowered body weight more than placebo.

    Peptide
    Survodutide
    Outcome
    DecreaseBody weight change
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Body weight weighted mean difference
    −6.7 kg
    survodutide vs placebo

    Source sentences

    Summary
    Survodutide also significantly decreased body weight (WMD: -6.7 kg, 95% CI [-10.0, -3.4], p < 0.001)
    2 context sentences
    Summary · context
    We systematically searched PubMed, Embase, the Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov for randomized controlled trials (RCTs) evaluating the efficacy and safety of survodutide up to 12 July 2025.
    Summary · context
    Six RCTs involving 1272 participants were included in this meta-analysis.
  5. 05HumanSystematic reviewEfficacy outcome

    In a meta-analysis of adults in six RCTs, survodutide significantly decreased waist circumference versus placebo (WMD -7.09 cm).

    In plain wordsIn a pooled analysis of adult trials, survodutide reduced waist size more than placebo.

    Peptide
    Survodutide
    Outcome
    DecreaseWaist circumference change
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Waist circumference weighted mean difference
    −7.09 cm
    survodutide vs placebo

    Source sentences

    Summary
    waist circumference (WMD: -7.09 cm, 95% CI [-9.44, -4.47], p < 0.001)
    2 context sentences
    Summary · context
    We systematically searched PubMed, Embase, the Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov for randomized controlled trials (RCTs) evaluating the efficacy and safety of survodutide up to 12 July 2025.
    Summary · context
    Six RCTs involving 1272 participants were included in this meta-analysis.
  6. 06HumanSystematic reviewEfficacy outcome

    In a meta-analysis of adults in six RCTs, the effects on body weight and waist circumference were enhanced at higher total weekly doses (above 2.4 mg) and longer treatment durations (over 16 weeks).

    In plain wordsIn a pooled analysis of adult trials, higher doses and treatment longer than 16 weeks gave larger drops in weight and waist size.

    Peptide
    Survodutide
    Outcome
    DecreaseBody weight and waist circumference by dose and treatment duration
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    with enhanced effects observed at higher total weekly doses (>2.4 mg) and longer treatment durations (>16 weeks).
    2 context sentences
    Summary · context
    We systematically searched PubMed, Embase, the Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov for randomized controlled trials (RCTs) evaluating the efficacy and safety of survodutide up to 12 July 2025.
    Summary · context
    Six RCTs involving 1272 participants were included in this meta-analysis.
  7. 07HumanSystematic reviewSafety outcome

    In a meta-analysis of adults in six RCTs, survodutide significantly increased gastrointestinal adverse events versus placebo.

    In plain wordsIn a pooled analysis of adult trials, survodutide caused more stomach and bowel side effects than placebo.

    Peptide
    Survodutide
    Outcome
    IncreaseGastrointestinal adverse events
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    the significant increase in gastrointestinal AEs and the associated risk of treatment discontinuation.
    3 context sentences
    Summary · context
    with gastrointestinal AEs being the most common
    Summary · context
    We systematically searched PubMed, Embase, the Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov for randomized controlled trials (RCTs) evaluating the efficacy and safety of survodutide up to 12 July 2025.
    Summary · context
    Six RCTs involving 1272 participants were included in this meta-analysis.
  8. 08HumanSystematic reviewSafety outcome

    In a meta-analysis of adults in six RCTs, survodutide did not significantly increase the incidence of serious adverse events versus placebo.

    In plain wordsIn a pooled analysis of adult trials, survodutide did not clearly cause more serious side effects than placebo.

    Peptide
    Survodutide
    Outcome
    No significant changeSerious adverse events
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    there was no significant increase in the incidence of serious AEs.
    2 context sentences
    Summary · context
    We systematically searched PubMed, Embase, the Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov for randomized controlled trials (RCTs) evaluating the efficacy and safety of survodutide up to 12 July 2025.
    Summary · context
    Six RCTs involving 1272 participants were included in this meta-analysis.
  9. 09HumanSystematic reviewEfficacy outcome

    In a meta-analysis of adults in six RCTs, survodutide significantly reduced BMI.

    In plain wordsIn a pooled analysis of adult trials, survodutide lowered body mass index.

    Peptide
    Survodutide
    Outcome
    DecreaseBody mass index change
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    significant reductions were observed in BMI, and modest reductions were noted in total cholesterol, triglycerides, and blood pressure.
    2 context sentences
    Summary · context
    We systematically searched PubMed, Embase, the Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov for randomized controlled trials (RCTs) evaluating the efficacy and safety of survodutide up to 12 July 2025.
    Summary · context
    Six RCTs involving 1272 participants were included in this meta-analysis.
  10. 10HumanSystematic reviewEfficacy outcome

    In a meta-analysis of adults in six RCTs, survodutide produced modest reductions in total cholesterol.

    In plain wordsIn a pooled analysis of adult trials, survodutide modestly lowered total cholesterol.

    Peptide
    Survodutide
    Outcome
    DecreaseTotal cholesterol change
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    modest reductions were noted in total cholesterol, triglycerides, and blood pressure.
    2 context sentences
    Summary · context
    We systematically searched PubMed, Embase, the Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov for randomized controlled trials (RCTs) evaluating the efficacy and safety of survodutide up to 12 July 2025.
    Summary · context
    Six RCTs involving 1272 participants were included in this meta-analysis.
  11. 11HumanSystematic reviewEfficacy outcome

    In a meta-analysis of adults in six RCTs, survodutide produced modest reductions in triglycerides.

    In plain wordsIn a pooled analysis of adult trials, survodutide modestly lowered triglycerides.

    Peptide
    Survodutide
    Outcome
    DecreaseTriglycerides change
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    modest reductions were noted in total cholesterol, triglycerides, and blood pressure.
    2 context sentences
    Summary · context
    We systematically searched PubMed, Embase, the Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov for randomized controlled trials (RCTs) evaluating the efficacy and safety of survodutide up to 12 July 2025.
    Summary · context
    Six RCTs involving 1272 participants were included in this meta-analysis.
  12. 12HumanSystematic reviewEfficacy outcome

    In a meta-analysis of adults in six RCTs, survodutide produced modest reductions in blood pressure.

    In plain wordsIn a pooled analysis of adult trials, survodutide modestly lowered blood pressure.

    Peptide
    Survodutide
    Outcome
    DecreaseBlood pressure change
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    modest reductions were noted in total cholesterol, triglycerides, and blood pressure.
    2 context sentences
    Summary · context
    We systematically searched PubMed, Embase, the Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov for randomized controlled trials (RCTs) evaluating the efficacy and safety of survodutide up to 12 July 2025.
    Summary · context
    Six RCTs involving 1272 participants were included in this meta-analysis.
  13. 13HumanSystematic reviewSafety outcome

    In a meta-analysis of adults in six RCTs, survodutide was associated with a higher risk of treatment discontinuation due to adverse events than placebo.

    In plain wordsIn a pooled analysis of adult trials, more people stopped survodutide because of side effects than stopped placebo.

    Peptide
    Survodutide
    Outcome
    IncreaseTreatment discontinuation due to adverse events
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    survodutide was associated with a higher risk of treatment discontinuation due to AEs
    2 context sentences
    Summary · context
    We systematically searched PubMed, Embase, the Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov for randomized controlled trials (RCTs) evaluating the efficacy and safety of survodutide up to 12 July 2025.
    Summary · context
    Six RCTs involving 1272 participants were included in this meta-analysis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.